P522 Prior pharmacotherapy patterns among patients with IBD in the USA initiating biologic therapy
ECCO'20 Vienna
2020
P523 Improvement of quality of life and continence in patients with distal ulcerative colitis treated by mesalazine: QUARTZ study
ECCO'20 Vienna
2020
P524 Administration and monitoring of biologic therapy in patients with inflammatory bowel disease: A national Danish survey
ECCO'20 Vienna
2020
P525 Rheumatoid arthritis treatment with filgotinib: Week 156 safety and efficacy data from a phase 2b open-label extension study
ECCO'20 Vienna
2020
P526 Body mass index and response to TNF-α inhibitors in inflammatory bowel disease
ECCO'20 Vienna
2020
P527 A review of adverse events associated with immunosuppressive treatments in inflammatory bowel disease patients
ECCO'20 Vienna
2020
P529 Natural history and management strategies of ulcerative colitis (UC) in a paediatric population: A 10-year review in a tertiary paediatric gastroenterology centre
ECCO'20 Vienna
2020
P530 Cost-effectiveness of vedolizumab SC vs. adalimumab for moderately to severely active ulcerative colitis
ECCO'20 Vienna
2020
P531 A retrospective audit of the inflammatory bowel disease specialist nurse-led telephone advice service
ECCO'20 Vienna
2020
P532 Measuring endoscopic activity in patients treated with vedolizumab for ulcerative colitis
ECCO'20 Vienna
2020
P533 Long-term quality of life after minimally invasive surgery for Crohn’s disease
ECCO'20 Vienna
2020
P534 Qualitative perspectives of parent and child participants from a trial of faecal microbiota transplant for paediatric ulcerative colitis
ECCO'20 Vienna
2020
P536 Early prediction of intravenous corticosteroid therapy failure in moderate–severe ulcerative colitis
ECCO'20 Vienna
2020
P537 Real-world long-term effectiveness of ustekinumab in Crohn’s disease: Results from the ENEIDA registry
ECCO'20 Vienna
2020
P538 Pregnancy outcomes in women with psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis treated with ustekinumab
ECCO'20 Vienna
2020